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Nitric oxide (NO) is a multi-functional messenger molecule
derived from the amino acid, L-arginine, in a reaction catalysed 
by NO synthase (NOS). There are three isoforms of NOS: the
calcium-dependent endothelial (eNOS) and neuronal (nNOS) and
the calcium-independent inducible (iNOS = NOS2). High levels of
NOS activity are present in several tumour cell lines as well as in
human cancer (Thomsen et al, 1994; 1995). An important function
of NO is to maintain or increase tumour blood flow via dilatation
of arteriolar vessels in some tumours (Fukumura et al, 1997). This
effect on tumour vasculature by NO enables vital nutrients and
oxygen to reach tumour cells and can result in a promoted tumour
growth in tumour cells that constantly release NO (Jenkins et al,
1995). Moreover, recent studies demonstrated another important
effect of NO in stimulating tumour angiogenesis (Fukumura and
Jain, 1998; Gallo et al, 1998; Thomsen and Miles 1998). Inhibition
of NO synthase might inhibit tumour neovascularization and in
this way reduce tumour growth.
Several authors demonstrated a selectively reduced tumour
blood flow in rodents treated orally with NOS inhibitors, such as
L-NAME (Andrade et al, 1992; Meyer et al; 1995; Tozer et al,
1998). Orucevic and Lala (1996a) demonstrated a concentration-
dependent anti-tumour effect of L-NAME in adenocarcinoma-
bearing mice. With other NO-inhibitors used as a single agent
anti-tumour effects have been demonstrated as well (Thomsen 
et al, 1997). The reduction in tumour blood flow leads to hypoxia
in tumour tissue and might thus be a useful strategy in anti-tumour
therapy in combination with other agents. For alkylating agents
such as melphalan and for cytokines such as tumour necrosis
factor alpha (TNF) it has been demonstrated that hypoxia can
potentiate the cytotoxic effects (Skarsgard et al, 1995; de Wilt 
et al, 1999).
To study the potential anti-tumour effects of systemic adminis-
tration of L-NAME we used a renal subcapsular tumour model,
using a colon carcinoma in WAG/Rij rats. Secondly, we examined
whether addition of L-NAME to melphalan and/or TNF in an
isolated limb perfusion (ILP) model could further improve
response rates. For this we used a well-established perfusion
model developed in our laboratory, which is based on the
successful treatment of patients with in-transit metastasis from
malignant melanoma (Liénard et al, 1992; Lejeune et al, 1993) and
irresectable or locally advanced soft-tissue sarcoma (Eggermont 
et al, 1996a; 1996b). For the last group of patients TNF has
recently been approved by the EMEA (European Medicine
Evaluation Agency) in the ILP setting in combination with
melphalan (Eggermont et al, 1999). In our ILP model strong
synergistic anti-tumour effects were previously demonstrated
when TNF was used in combination with two different chemother-
apeutics (melphalan or doxorubicin) (Manusama et al, 1996; de
Wilt et al, 1999; van der Veen et al, 2000). The synergistic anti-
tumour effects were accompanied by higher intratumoural
melphalan concentrations after perfusion with TNF compared to
perfusions with melphalan alone (de Wilt et al, 2000). The
observed effects in rats corresponded well to ILP in patients in
terms of response rate and histopathological observations
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doi: 10.1054/ bjoc.2000.1447, available online at http://www.idealibrary.com on (Manusama et al, 1996; Nooijen et al, 1996). Therefore, this rat
model is applied to study usefulness of additional agents in ILP to
improve response rates or find synergy between agents, which
allow lower dosages of toxic agents like TNF.
MATERIALS AND METHODS
Animals
Male inbred BN and Wag/Rij rats, weighing 250–300 g, obtained
from Harlan-CPB (Austerlitz, the Netherlands) were used. The rats
were fed a standard laboratory diet ad libitum (Hope Farms,
Woerden, the Netherlands) and were housed under standard condi-
tions. The experimental protocols adhered to the rules outlined in
the Dutch Animal Experimentation Act (1977) and the published
‘Guidelines on the protection of Experimental Animals’ by the
council of the European Committee (1986). The protocol was
approved by the committee on Animal Research of the Erasmus
University Rotterdam, The Netherlands.
Drugs
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, UK)
was diluted in 10 ml diluent solvent. Further dilutions were made
in 0.9% NaCl to give a volume of 0.2 ml in the perfusion circuit 
(= 40 µ g). Recombinant human TNF alpha (TNF) was provided 
by Boehringer (Ingelheim, Germany) having a specific activity of
5.8 × 107 U mg–1 as determined in the murine L-M cell assay
(Kramer and Carver, 1986). Endotoxin levels were < 1.25 endo-
toxin units (EU) per mg protein. Nω -nitro-L-arginine methyl ester
(L-NAME) (10 g per vial, Sigma, the Netherlands) was dissolved
in 0.9% NaCl and administered intraperitoneally at a concentration
of 80 mg kg–1 or dissolved in Haemaccel and added to the
perfusate to provide a concentration of 2 mg ml–1.
Western blot analysis for detection of inducible nitric
oxide synthesis (iNOS)
Protein extracts were prepared from tissue pieces crushed under
liquid nitrogen and homogenized on ice in RIPA buffer (50 mM
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, and
0.1% SDS) containing 1 mM DTT, 0.1 mM PMSF and 10 mg l–1
aprotinin. Supernatant was prepared by centrifugation at 
120 000 g for 10 min, and protein concentrations were determined
with the Coomassie Plus Protein Reagent (Pierce IL, USA). One-
dimensional Western blot analysis was carried out, for detection of
iNOS (Towbin et al, 1979). Briefly, sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) was carried out in the
Biorad minigel system with 7% polyacrylamide gel using 300 µ g
of soluble protein extracts. Electrophoresed proteins were
transfered to a PVDF membrane (Millipore Corp, MA, USA) and
unspecific binding was blocked by incubation of the membrane in
TBST (10 mM Tris, 150 mM NaCl, and 0.05% Tween 20) plus 2%
BSA for 1 h at room temperature. The membranes were probed
with a polyclonal rabbit anti-rat iNOS antibody (N-20, Santa Cruz
Biotechnology Inc, CA, USA), diluted 1:40 000 in TBST. iNOS
antibody was detected using a secondary mouse antibody to rabbit
which was alkaline phosphatase labelled (Sigma, St. Louis
MO, USA). Colour development was performed using the
alkaline phosphate substrate nitroblue tetrazolium (NBT) and 
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) in AF-buffer until
colour was fully developed (Boehringer Mannheim, Mannheim,
Germany).
Immunohistochemical staining of tumour samples for
iNOS.
Portions of BN-175 tumour samples embedded in paraffin and
4µ m section were collected on clean glass slides. Slides were
incubated with rabbit polyclonal anti iNOS (NOS2) antibody (N20,
Santa Cruz), followed by incubation with a secondary goat-
anti-rabbit peroxidase conjugated antibody (Jackson Immuno-
Research Laboratories Inc, West Grove PA, USA). Colour was
developed using DAB reagent according to the manufacturer
(Sigma).
Renal sub-capsular tumour model
Renal sub-capsular tumour model was established in male rats of
the inbred WAG-Rij strain introducing 8 mg of solid CC531 colon
carcinoma under the capsule of both kidneys under microscopic
vision, according to a previously described method (Marquet 
et al, 1984). Treatment was started 1 day after implantation by
intraperitoneal injection of 80 mg kg–1 L-NAME twice daily.
Control rats were treated with a phosphate-buffered saline (PBS)
solution. After 10 days of treatment rats were sacrificed and
kidney tumours weighed. Both groups consisted of eight rats and
all animals were evaluable. With respect to systemic toxicity of 
L-NAME, body weights of the rats were measured 4 and 
10 days after treatment and creatinine and urea levels were
determined at sacrifice.
Isolated limb perfusion model
The technique we used has been published previously (Manusama
et al, 1996). Briefly, a spontaneous, non-immunogenic BN-175
sarcoma was used and implanted subcutaneously in the right hind
limb in BN rats (Kort et al, 1984). Perfusion was performed at a
tumour diameter of 13 ± 3 mm at least 7 days after implanta-
tion. Animals were anaesthetized with Hypnorm (Janssen
Pharmaceutica, Tilburg, The Netherlands) and 50 IU of heparin
were injected intravenously to prevent coagulation in the perfusion
circuit. A warm water mattress was applied to maintain a constant
temperature of 38–39° C in the hind limb during perfusion. The
femoral artery and vein were cannulated with silastic tubing 
0.30 mm ID, 0.64 mm OD; 0.64 mm ID 1.15 mm OD respectively,
Dow Corning, Michigan, USA). Collaterals were occluded by a
groin tourniquet and isolation time started when the tourniquet was
tightened. An oxygenation reservoir and a roller pump were
included into the circuit. The perfusion commenced with 5 ml
Haemaccel (Behring Pharma, Amsterdam, the Netherlands) and
the haemoglobin (Hb) content of the perfusate was 0.9 mmol l–1.
L-NAME was dissolved in the perfusate, melphalan and TNF were
added as boluses to the oxygenation reservoir. A roller pump (type
505 U; Watson Marlow, Falmouth, UK) recirculated the perfusate
at a flow rate of 2.4 ml min–1. A washout with 2 ml oxygenated
Haemaccel was performed at the end of the perfusion. In the rat
collateral circulation via the internal iliac artery to the leg is so
extensive that it allows ligation of the femoral vessels without
detrimental effects. After ligation of the femoral artery back-flow
from the femoral vein was seen in all rats immediately after release
of the tourniquet.
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measurement. Tumour volume was calculated as 0.4 (A2B), where
B represents the longest diameter and A the diameter perpendic-
ular to B.
Assessment of tumour response
The classification of tumour response was: progressive disease
(PD) = increase of tumour volume (> 25%) within 4 days; no
change (NC) = tumour volume equal to volume during perfusion
(in a range of –25% – +25%); partial remission (PR) = decrease of
tumour volume (–25 –– 90%); complete remission (CR) = tumour
volume 0–10% of volume during perfusion or necrosis.
Statistical analysis
Mann–Whitney U test was used to compare tumour volumes in
different animal groups and to compare different tumour responses
in different groups. Calculations were performed on a personal
computer using GraphPad Prism and SPSS for Windows 95.
RESULTS
iNOS Western blot
Western blot analysis of tumor extracts demonstrated distinct
iNOS bands at approximately Mr 125 000–138 000 (Ambs et al,
1998). iNOS was demonstrated in tumour tissue but not in muscle
tissue (Figure 1). The results suggest that iNOS is more abundant
in tumour tissue than in normal muscle tissue in the rat and suggest
an important role for iNOS in tumour tissue.
iNOS immunohistochemistry
The source of intratumoural NO production was determined 
on BN-175 tumour slides by immunohistochemistry with a
polyclonal anti-NOS2 antibodies. In Figure 2 clear production of
iNOS in tumour cells is shown. These results correspond with in
vitro observations showing NO production by BN-175 tumour
cells after stimulation with mitogens.
Renal sub-capsular tumour model
Systemic treatment with L-NAME resulted in a statistically signi-
ficant growth inhibition of CC-531 colon carcinoma growing
under the kidney capsule compared to untreated rats (44.8 vs 64.9
g; P < 0.005) (Fig. 3). Ten days after treatment, body weight of rats
were statistically not significantly different between both groups
(–13.0 ± 5.4 g after L-NAME treatment vs –5.5 ± 3.1 g after sham
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Figure 2 Paraffin tissue sections from soft-tissue sarcoma BN-175 stained
with anti-NOS2 (iNOS). Nitric oxide synthesis-positive tumour cells (brown
staining) can be found throughout the section as shown in (A) and (B)
(respectively original magnification of × 16 and × 40), whereas infiltrating
cells stain negative. No staining was found in negative control slides in 
which non-specific IgG was used (C, original magnification × 40).
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Figure 1 Western blot analysis showing a distinct band at approximately
125–138 kDtreatment). At day 10 after intraperitoneal administration creati-
nine and urea levels were statistically significantly different from
the control group (creatinine 28.5 ± 4.3 vs 68.5 ± 8.5 µ mol l–1
(P < 0.005) and urea 5.6 ± 0.4 vs 8.1 ± 1.3 mmol l–1 (P < 0.05) in
the control and L-NAME groups respectively). This increase in
urea and creatinine levels indicate a decrease in renal function that
might be the result of impaired renal blood flow.
Tumour response after isolated limb perfusions with L-
NAME, TNF and/or melphalan
We studied the possible beneficial role of L-NAME on tumour
response in ILP. Synergy between melphalan and TNF in ILP was
previously demonstrated in our laboratory and could be confirmed
in this study for which we used 10 rats in each study group (Table 1)
(de Wilt et al, 1999; Manusama et al, 1996). Sham perfusion did
not inhibit tumour growth and progressive disease was observed 
in all rats. Perfusions with L-NAME as a single agent, however,
resulted in tumour growth arrest after 5 days in four of 11 rats,
which was statistically significant different from sham ILP 
(P = 0.02), resulting in a growth delay as shown in Figure 4A.
ILP with TNF alone resulted in progressive disease in all
animals, similar as in sham perfused rats. Addition of L-NAME to
TNF improved tumour responses from 0–64%, which was signi-
ficantly different from TNF alone (P < 0.001).
After perfusion with melphalan tumour growth was arrested in
eight of 10 animals (no change) and progressive tumour growth
was observed in two of 10 animals. Melphalan in combination
with L-NAME showed a 63% partial and complete response rate,
which was significantly different from melphalan alone (P =
0.001).
TNF and melphalan have a synergistic anti-tumour effect and
are highly effective with a 70% partial and complete response
rate. Addition of L-NAME to the combination of TNF and
melphalan, however, could further improve tumour responses
to 100% 5 days after treatment, but this was not statistically
significant (P = 0.3) After perfusion with TNF and melphalan
recurrent tumour growth was demonstrated in all animals after a
mean of 9 ± 2 days. When L-NAME was added to the perfusate
one animal did not show tumour growth 50 days after ILP,
whereas recurrent tumour growth occurred in nine of 10 animals
after a mean of 20 ± 7 days (data not shown). The observed
response rate was therefore not only more pronounced but the
anti-tumour effect extended for a significantly longer period
after perfusion.
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Figure 3 Tumour weight (mean +/– SEM) of renal subcapsular CC531
adenocarcinoma after 10 days treatment with sham (n = 8) or 80 mg kg–1
L-NAME intraperitoneal injection (n = 8)
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Figure 4 (A, B and C) Growth curves of BN175 sarcoma after isolated
limb perfusion with sham (  ; n = 10), 10 mg L-NAME (   ; n = 11), 50 µ g TNF
(  ; n = 10), 50 µ g TNF with 10 mg L-NAME (   ; n = 11), 40 µ g melphalan 
(  ; n = 10), 40 µ g melphalan with 10 mg L-NAME (   ; n = 16), 50 µ g TNF in
combination with 40 µ g melphalan (  ; n = 10) and 50 µ g TNF in combination
with 40 µ g melphalan and 10 mg L-NAME (   ) n = 10). Growth curves of
sham and L-NAME perfused rats is depicted in all figures to allow
comparison (mean +/– SEM of tumour volumes are shown)
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ADISCUSSION
The results of the present study show a significantly reduced
tumour growth after intraperitoneal administration of the nitric
oxide (NO) inhibitor L-NAME in tumour-bearing rats. The growth
inhibition of L-NAME in the renal sub-capsular assay may be
partially due to a decrease in renal blood flow. Kassab et al (1998)
previously demonstrated a decreased renal blood flow after admin-
istration of NO inhibitors, which is confirmed in our study by
elevated creatinine and urea levels. Therefore, conclusions
concerning anti-tumour effect of NO inhibitors from the data
obtained in the renal sub-capsular assay cannot be drawn, but these
data strongly suggest a growth inhibitory effect on the tumour by
NO inhibitors.
In the experiments in which L-NAME was used in an isolated
perfusion setting in sarcoma-bearing rats a decreased tumour
growth was demonstrated when L-NAME was used alone.
Moreover, strong synergy was observed when L-NAME was used
in combination with either TNF (response rates improved from
0–64%) or melphalan (response rates improved from 0–63%).
Even in the setting of the strongly synergistic combination of
melphalan and TNF (response rates: 70%) the addition of L-NAME
enhanced response rates to 100%. Moreover, when L-NAME was
added to the perfusion tumour growth recurrences occurred at
approximately 20 days after ILP, whereas tumours recur after a
mean of 9 days after ILP with TNF and melphalan alone.
The anti-tumour effects of L-NAME in the highly vascularized
BN-175 soft tissue sarcoma found in this study are similar to
previously demonstrated effects of NO inhibitors in mice
(Orucivic and Lala, 1996a; Thomsen et al, 1997). The function of
NO inhibition in tumour biology, however, is not clear since NO
has a multifactorial role in the vascular, nervous and immune
system and is demonstrated in many different cell lines and
tissues. High concentrations of NO synthase (NOS) are present in
different tumour cell lines, where the enzyme activity correlates
with the tumour grade (Thomsen et al, 1995; Ambs et al, 1998).
We demonstrated iNOS to be present in the BN-175 soft-tissue
sarcoma and not in the surrounding muscle tissue using a Western
blott analysis and immunohistochemistry. High levels of NO
induced by iNOS suppresses metastatic potential and directly
correlates with cytotoxicity in several studies (Xie and Fidler,
1999). In contrast, Jenkins et al (1995) found a promotion of
tumour growth in tumour cells that constantly produce NO.
Recently others demonstrated that iNOS activity was higher in
metastasizing head and neck cancer tissue compared to normal
tissue, suggesting an important role for NO in tumour biology
(Gallo et al, 1998).
One mechanism of NO is to increase or maintain tumour blood
flow and therefore supply nutrients and oxygen to the tumour
(Buttery et al, 1993). In studies in which rodents were treated 
with NO inhibitors, a selectively reduced tumour blood flow was
demonstrated (Andrade et al, 1992; Tozer et al, 1997). This
decreased flow is initiated by a decreased central tumour perfusion
in some tumours (Meyer et al, 1995) or a decreased peripheral
perfusion in others (Fukumura et al, 1997). Localization of NOS is
cell- and tumour-dependent and as a result the response to NO
inhibitor is likely to be heterogeneous and tumour-dependent.
Horsman et al (1996) did not find a decrease in oxygenation status
of tumours treated with NO inhibitors despite a significantly
reduced tumour blood flow. However, Wood et al (1994) demon-
strated that reduced flow by an NO inhibitor decreased the energy
status of several murine tumours, whereas the normal skin was
unaffected. Moreover, they found evidence for an increase in
tumour sensitivity to a level sufficient to enhance the efficacy of
cytostatic agents (Wood et al, 1994). In vivo studies have shown
that reduction of tumour blood flow with agents such as
hydralazine can enhance the tumouricidal effect of melphalan. In
vitro studies on human tumour cells also demonstrated a potentia-
tion of melphalan cytotoxicity by both hypoxia and acidic pH
(Skarsgard et al, 1995). We previously demonstrated promotion of
TNF as well as melphalan anti-tumour effects with hypoxia in
soft-tissue sarcoma-bearing rats in ILP (de Wilt et al, 1991). The
enhanced anti-tumour effect of L-NAME with melphalan and/or
TNF as we describe in this study might thus be explained by
hypoxia that is induced by the reduced tumour blood flow.
More recently an important role of NO in tumour angiogenesis
was suggested (Fukumura and Jain, 1998; Thomsen and Miles,
1998). NO was shown to promote tumour progression by down-
regulating tissue inhibitors of metalloproteinases (TIMP) and up-
regulating matrix metalloproteinases (MMP) (Orucevic et al,
1999). Gallo et al (1998) demonstrated that inhibition of NO by 
L-NAME in squamous cell carcinoma transplanted in the rabbit
cornea decreased tumour-induced angiogensis. Similar reduced
tumour angiogenesis by L-NAME was demonstrated in a highly
metastatic murine breast cancer model by Jadeski and Lala (1999).
Since BN-175 is a highly vascularized and fast-growing tumour,
inhibition of neovascularization in this tumour might well be a
good explanation for the significant tumour responses and later 
re-growth after perfusion with L-NAME in combination with
melphalan and TNF.
Leukocyte–endothelial interactions in tumour vessels is a major
limitation of immune therapy or host immune response against
tumours. NO has a possible role in down-regulating these actions
and inhibition of NO was demonstrated to increase leuko-
cyte rolling and adhesion to the vessel wall in tumours signi-
ficantly (Fukumura et al, 1995). Lejeune et al (1994) found an
enhanced tumour-infiltrating lymphocyte proliferation in rat
colon adenocarcinoma when NO production was inhibited with 
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Table 1 Tumour response of BN-175 soft-tissue sarcoma after isolated limb perfusion
Tumour response Sham Sham + LNAME TNF TNF + LNAME Melphalan Mel + LNAME TNF + Melphalan TNF + Mel + LNAME
(n = 10) (n = 11) (n = 10) (n = 11) (n = 10) (n = 16) (n = 10) (n = 10)
Progressive disease 10 7 10 3 2 1 1 –
No change – 4 – 18 5 3 –
Partial response –––6 – 51 3
Complete response –––1 – 56 7
Percentage response ––– 64% – 63% 70% 100%
(partial/complete)
Perfusions were performed with 50 µ g TNF, 40 µ g melphalan and 10 mg L-NAME under constant temperature (38–39° C) for 30 minL-NAME. Previous work in our laboratory and by others
demonstrated that TNF-induced anti-tumour effect might be
leukocyte-dependent (Renard et al, 1994; Fukumura et al, 1995;
Manusama et al, 1998). Increased leukocyte–endothelial interac-
tions induced by L-NAME might therefore be another reason for
the additional anti-tumour effect of L-NAME to TNF. Orucevic
and Lala (1996b) previously demonstrated an increased anti-
tumour effect when L-NAME was combined with another
cytokine (e.g. IL-2). Meyer et al (1995) suggested that the vascular
effects they observed in tumours treated with L-NAME was not
only due to leukocyte adhesion but also to the development of
microthrombi resulting from platelet aggregation. Since platelet
aggregation is an important event in the TNF anti-tumour response
as well, this mechanism might be another reason for the enhanced
effect of L-NAME with TNF (Renard et al, 1995; Nooijen et al,
1996).
In conclusion, we demonstrate that L-NAME leads to a reduc-
tion in tumour growth both after systemic administration as well as
in ILP against a non-immunogenic soft-tissue sarcoma in the rat.
The observed high response rates with the addition of L-NAME to
melphalan and TNF are promising for the use of L-NAME in the
clinical setting. Since the dose-limiting toxic effect of TNF in
cancer therapy is mainly hypotension induced by NO production
in endothelial cells, systemic L-NAME may favourably alter this
toxicity which could result in a higher maximum tolerated dose
(Kilbourn and Belloni, 1990; Kilbourn et al, 1990). This might
open therapeutical options for TNF cancer treatment in other
settings than in ILP. Optimization of NOS inhibitor concentrations
and kinetics will be necessary to fully exploit this potential
therapy.
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